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394Drug-eluting balloons for femoropopliteal lesions
show better performance in de novo stenosis or
occlusion than in restenosis
Monika Herten, PhD,a Giovanni B. Torsello, PhD,a,b Eva Schönefeld, MD,a,b Britta Imm,a
Nani Osada, PhD,a and Stefan Stahlhoff, MD,a Münster, Germany
Objective: Although drug-eluting balloons (DEBs) have shown promising results treating de novo (DN) atherosclerotic
lesions and appear to have been widely adopted in Europe, their long-term efﬁcacy in the broad spectrum of femo-
ropopliteal restenosis (RE) remains to be proven. The purpose of the study was to assess the efﬁcacy of paclitaxel-DEBs in
restenotic (stented and nonstented) vs DN stenotic femoropopliteal arteries.
Methods: The study prospectively enrolled 100 patients undergoing femoropopliteal endovascular intervention by DEB for
RE or DN stenosis. Patients who received additive atherectomy were excluded. The primary end point was the primary
patency (PP) rate at 12 months. Secondary end points were sustained clinical improvement and clinically driven target
lesion revascularization.
Results: DEBs were used to treat 105 limbs for intermittent claudication (82 [78%]) or critical limb ischemia (23 [22%])
in 100 patients. Of these, 111 lesions were DN stenosis (46 [41%]) or RE (65 [59%]). The overall PP was 86% at
6 months and 74% at 12 months. PP of DN stenosis was higher at 6 months (93% vs 81%) and was signiﬁcantly (P [
.021) better than RE at 12 months (85% vs 68%). Sustained clinical improvement based on Rutherford classiﬁcation was
signiﬁcant in both groups (P < .001). Target lesion revascularization was signiﬁcantly lower in DN stenosis compared
with RE at 12 months (15% vs 32%; P [ .021).
Conclusions: DEB angioplasty is an effective therapy for DN femoropopliteal lesions. The results of DEB angioplasty for
RE are inferior compared with DN stenosis after 12 months. Nevertheless, results of DEB angioplasty for RE seem
comparable with technically more demanding literature-derived strategies. (J Vasc Surg 2015;61:394-9.)The role of the drug-eluting balloon (DEB) in the ther- angioplasty signiﬁcantly reduced the TLR to 4% to 13% at
apy for atherosclerotic lesions is well established. Recent ran-
domized clinical trials (RCTs) showed paclitaxel (PTX)-
DEB angioplasty was superior compared with standard un-
coated percutaneous transluminal angioplasty (PTA). Re-
sults demonstrated effectiveness in above-the-knee
lesions,1-5 whereas contradictory outcomes in safety and ef-
ﬁcacy have been reported for below-the-knee lesions.6,7 The
target lesion revascularization (TLR) rate after PTA of the
femoropopliteal region ranges between 22% and 37% at
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most lesions treated within the published studies and regis-
tries have been de novo (DN) stenosis, ranging from 63% to
100% in above-the-knee1-3,5,8,9 and from 65% to 100% in
below-the-knee studies.6,7,10
For femoropopliteal in-stent restenosis (RE), some
data indicate a promising role of DEBs, with a TLR rate
at 1 year of 7.9%,11 9.8%,12 and 13.6%.13 DEBs in combi-
nation with directed atherectomy achieved TLR rates of
10%14 and 15.3%.15 However, long-term patency rates
are still missing. The purpose of the study was to assess
the efﬁcacy of PTX-DEB in RE (stented and nonstented)
vs DN stenotic femoropopliteal arteries.
METHODS
This study was conducted in agreement with the Inter-
national Conference on Harmonization Guidelines, Good
Clinical Practice, Declaration of Helsinki, and Ethics Com-
mittee requirements.
Study population. Between October 2009 and
February 2013, 111 lesions in 100 consecutive patients
with intermittent claudication (78%) or critical limb
ischemia (22%) underwent femoropopliteal endovascular
intervention with intention to treat by DEB angioplasty
in two centers. Clinical data were collected prospectively
(Table I). All patients provided written informed consent
before the intervention.
Table I. Baseline demographic and clinical data
Variablea RE DN P value
Patients (n ¼ 100) 61 (61) 39 (39)
Limbs (n ¼ 105) 63 (60) 42 (40)
Age, years 69.9 6 11.0 66.3 6 10.8 .104
Male 35 (57) 23 (59) .875
Arterial hypertension 50 (82) 33 (85) .731
Diabetes mellitus 23 (38) 10 (26) .211
History of smoking 15 (25) 22 (56) .001
Hyperlipidemia 35 (57) 23 (59) .875
Obesity 15 (25) 15 (38) .140
Dialysis 1 (2) 0 (0) 1.000
Limbs
Intermittent claudication 45 (71) 37 (88) .055
Critical limb ischemia 18 (29) 5 (12) .055
Preinterventional
Rutherford classiﬁcation 3 (1, 5) 3 (2, 5) .179
ABI 0.57 6 0.29 0.68 6 0.25 .048
ABI, Ankle-brachial index; DN, de novo (the DN stenosis group included
only native stenotic vessels); RE, restenosis (the RE group included stented
and nonstented restenotic arteries).
aContinuous data are shown as mean 6 standard deviation or as median
(minimum, maximum) and categoric data as number (%).
Fig 1. Study ﬂow. ABI, Ankle-brachial index; DEB, drug-eluting
balloon; FU, follow-up; ISR, in-stent restenosis.
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cording to their etiology as RE (n ¼ 65), in-stent or not
in-stent, or DN (n ¼ 46; Fig 1). Plaque excision with and
without DEBs was performed only in short lesions. No
other procedures were performed for RE during the study
period. The evaluation excluded patients who received
additional atherectomy. Lesions characteristics are reported
in Table II. Because the RE group comprised patients with
lower baseline ankle-brachial indices (ABIs) and with
longer lesions, those lesions were at higher risk.
Procedure and devices. Vascular access was accom-
plished by a contralateral or ipsilateral transfemoral
approach. Heparin (5000 units) was given after vascular ac-
cess was performed. Predilatation PTA was systematically
performed before treatment with IN.PACT Admiral (Med-
tronic GmbH, Meerbusch, Germany) or Freeway (Eurocor
GmbH, Bonn, Germany) PTX-DEB systems. Both DEBs
contained PTX at a concentration of 3 mg/mm.2 The
procedural details are listed in Table II. In case of persistent
ﬂow-limiting dissections or recoil after balloon dilatation,
additional self-expanding nitinol stents were implanted as
provisional stenting.
End points and deﬁnitions. Primary end point was
the primary patency (PP), deﬁned as freedom from RE
>50% of the target lesion by duplex ultrasound imaging
based on a peak systolic velocity ratio >2.4 m/s at the
lesion site. Hemodynamic parameters by duplex ultrasound
imaging were combined with, at minimum, one clinically
driven parameter: decrease of Rutherford class $1 or ABI
decrease >20%. In a subanalysis, we analyzed PP with or
without provisional stenting.
Secondary end points were secondary sustained clinical
improvement and symptom-driven TLR at 12 months.
Secondary sustained clinical improvement was deﬁned as
an improvement shift of the Rutherford classiﬁcation of$1 category for claudicant patients and rest pain resolution
for patients with critical limb ischemia. Clinically driven
TLR expresses the need for repeated procedures (surgical
or endovascular) at the site of the previously treated lesion.
Statistical analysis. Statistical analysis was performed
using SPSS 22.0 software (IBM Corp, Armonk, NY).
Continuous variables are presented as mean6 standard de-
viation and categoric variables as frequency and percentage.
Ordinal parameters (Rutherford classiﬁcation) are
expressed as median with the minimum and maximum or
with the interquartile range (25th percentile-75th percen-
tile). Analysis of normal distribution of each continuous
variable was performed by the Kolmogorov-Smirnov test
before further statistical testing. The Mann-Whitney U test
was used for comparison of nonparametric values between
two study groups. Paired continuous nonparametric data
were compared by the Wilcoxon test; proportions were
compared by c2 test and by Fisher exact test, as appro-
priate. Survival and patency rates were determined with the
Kaplan-Meier estimate in a time-to-event model. The log-
rank test was used for estimating the effect of variables on
the clinical outcome. Differences were considered signiﬁ-
cant at P < .05.RESULTS
Baseline characteristics of patients and lesions. The
RE and DN groups did not differ signiﬁcantly except for a
signiﬁcantly higher rate of smokers in the DN group. Pre-
interventional Rutherford classes were comparable between
the groups. Baseline ABIs were signiﬁcantly lower in the
RE than in the DN group (P ¼ .048). Lesion and
Table II. Lesion characteristics and procedural detail
Variablea RE DN P value
Lesions (n ¼ 111) 65 (59) 46 (41)
In-stent RE 46 (71)
Superﬁcial femoral artery 49 (75) 29 (64) .161
Popliteal artery involved 16 (24) 17 (37) .161
Lesion length, mm 99 6 76 77 6 68 .050
Degree of stenosis, % 82 6 16 81 6 18 .900
Total occlusion 16 (25) 12 (27) .935
DEB lesions, No. 1.2 6 0.6 1.3 6 0.7 .191
Length of PTX-DEB, mm 129 6 71 122 6 78 .289
PTX-DEB diameter, mm 4.9 6 0.5 4.9 6 0.6 .553
Inﬂation pressure, bar 13 6 7 12 6 6 .507
Inﬂation time, seconds 148 6 80 159 6 52 .223
DEB, Drug-eluting balloon; DN, de novo (the DN stenosis group included
only native stenotic vessels); PXT, paclitaxel; RE, restenosis (the RE group
included stented and nonstented restenotic arteries.
aContinuous variables are presented as mean 6 standard deviation and
categoric variables as number (%).
Fig 2. Primary patency (PP) rate by Kaplan-Meier method after
drug-eluting balloon (DEB) intervention of restenotic (RE) or de
novo (DN) stenotic femoropopliteal arteries. Standard errors were
#3.7% for RE and #6.4% for DN.
Table III. Primary patency (PP) at 6 and 12 months,
including or excluding provisional stenting in restenotic
(RE) or de novo (DN) stenotic femoropopliteal arteriesa
PP
Both
groups
Including bailout
stenting
Excluding bailout
stenting
RE DN
P value
RE vs DN RE DN
P value
RE vs DN
Patients, No. 100 61 39 53 27
6 months, % 86 81 93 .093 80 97 .028
12 months, % 74 68 85 .021 67 89 .007
aThe DN stenosis group included only native stenotic vessels and the RE
group included stented and nonstented restenotic arteries.
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no signiﬁcant difference in parameters apart from the
longer lesion length in the RE group (P ¼ .05). IN.PACT
and Freeway were overall used in 95 and 16 cases,
respectively, and their distribution was not signiﬁcantly
different across the RE (80% and 20%) vs DN groups (93%
and 7%; P ¼ .057).
Additional stenting was performed in 20 lesions (18%)
and was necessary signiﬁcantly more often in DN (12 le-
sions [28%]) than in RE (eight lesions [7%]; P ¼ .007).
Primary end point. Overall PP was 86% and 74% at 6
and 12 months after DEB application. PP of DN was better
than of RE at 6 months (93% vs 81%, P ¼ .093) and was
signiﬁcantly better at 12 months (85% vs 68%; P ¼ .021;
Fig 2 and Table III). Subanalysis of PP without provi-
sional stenting revealed superior rates for DN at 6 months
(97% vs 80%; P ¼ .028) and at 12 months (89% vs 67%;
P ¼ .007; Table III).
Secondary end point. The ABI signiﬁcantly
improved, from 0.61 at preintervention to 0.87 at
12 months (P ¼ .037). Within the groups, ABI increased
signiﬁcantly in RE, from 0.57 6 0.29 at preintervention
to 0.85 6 0.20 at 12 months (P < .001) and in DN
from 0.68 6 0.25 to 0.90 6 0.12, respectively (P <
.001; Table IV). In both groups, secondary sustained
clinical improvement was demonstrated by the shift of
at least 1 category of the Rutherford classiﬁcation at
12 months (P < .001) without difference between the two
groups (RE, 78%; DN, 83%; P ¼ .568; Table V). TLR after
treatment of DN was lower, at 7% and 15% at 6 and
12 months, respectively, compared with 19% and 32% for
RE (Table VI). Subanalysis of TLR without provisional
stenting revealed superior rates for DN at 6 (3% vs 20%,
P ¼ .028) and 12 months (10% vs 32%; P ¼ .007).
No amputation was necessary at 12 months of follow-
up. No major adverse cardiac or cerebrovascular events
occurred during the hospital stay. Seven patients died for
reasons not related to the intervention, ﬁve from the RE
group and two from the DN group. Fig 3 shows that thecumulative survival rates by Kaplan-Meier method of
both groups did not differ signiﬁcantly (P ¼ .965).
DISCUSSION
The present study shows that PTX-DEBs are safe and
effective in treating femoropopliteal lesions. However, the
results are signiﬁcantly better after treatment of DN than
after RE lesions.
Treatment of femoropopliteal restenotic lesions, partic-
ularly after stenting, is associated with inferior outcomes
and a higher rate of RE recurrence vs DN lesions. In our
study, the results of the DN group are in line with RCTs
comparing DEB angioplasty with uncoated-balloon PTA
Table V. Comparative Rutherford categories, before and
at 12 months’ follow-up after drug-eluting balloon
(DEB) intervention, of restenotic (RE) or de novo (DN)
stenotic femoropopliteal arteries
Rutherford classiﬁcationa RE DN
P value
RE vs DN
Before DEB 3 (3-4) 3 (3-3) .201
At 12 months 1 (0-3) 1 (0-2) .814
Improved outcome at
12 months
38/48 (80) 26/32 (81) .819
P value before vs 1 year <.001 <.001
aContinuous values are median (interquartile range [25th-75th percentile])
and categoric values are number (%).
Table VI. Target limb revascularization (TLR) at 6 and
12 months including or excluding provisional stenting in
restenotic (RE) or de novo (DN) stenotic
femoropopliteal arteriesa
TLR rate
Including bailout
stenting
Excluding bailout
stenting
Both
groups RE DN
P value
RE vs DN RE DN
P value
RE vs DN
Patients, No. 100 61 39 53 27
6 months, % 14 19 7 .093 20 3 .028
12 months, % 26 32 15 .021 32 10 .007
aThe DN stenosis group included only native stenotic vessels, and the RE
group included stented and nonstented RE arteries.
Fig 3. Cumulative survival rates byKaplan-Meiermethodafter drug-
eluting balloon (DEB) intervention (including provisional stenting)
of restenotic (RE) or de novo (DN) stenotic femoropopliteal arteries.
Standard errors were#6.1% for RE and#6.8% for DN.
Table IV. Comparative ankle-brachial index (ABI)
values, before and and at 12 months’ follow-up after
drug-eluting balloon (DEB) intervention, of restenotic
(RE) or de novo (DN) stenotic femoropopliteal arteries
ABI valuea RE DN P value
Baseline 0.57 6 0.29 0.68 6 0.25 .048
At 12 months 0.85 6 0.20 0.90 6 0.12 .422
Difference
12 months e
baseline
0.25 6 0.25 0.22 6 0.28 .419
Improved outcome
at 12 months
37/46 (80) 25/34 (73) .732
P value baseline vs
12 months
<.001 <.001
aData are shown as mean 6 standard deviation or as number (%).
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domized Pilot Trial [FemPac Trial], Local Taxan with
Short Time Contact for Reduction of Restenosis in Distal
Arteries [THUNDER Trial], Paclitaxel-coated Balloons in
Femoral Indication to Defeat Restenosis [PACIFIER
Trial], The Lutonix Paclitaxel-Coated Balloon for the Pre-
vention of Femoropoliteal Restenosis [LEVANT-I Trial],
First in Man study to assess the safety and performance
of the coated Passeo-18 Lux Paclitaxel releasing PTA
Balloon Catheter vs an uncoated balloon catheter in pa-
tients with stenosis and occlusion of the femoropopliteal
arteries [BIOLUX P1 Trial]),1-4 while outcomes of the
RE group appear to be less favorable compared with
what has previously been reported for in-stent RE. In
particular, TLR rates after treatment of DN stenosis are
reported to be 6.9% and 15.1% at 6 and 12 months,
respectively.
Despite the signiﬁcant occurrence of femoropopliteal
RE in clinical practice, few data are available on the effec-
tiveness of DEB under these conditions. Stabile et al11 re-
ported excellent results after treatment of in-stent RE with
DEB angioplasty (7.9% TLR at 1 year)11 in the Femoral
Artery In-Stent Restenosis (FAIR) trial of 9.2%,12 and Liis-
tro et al13 reported 13.6%. In our study, TLR of the RE
group (with 70% proportion of in-stent RE) was 19% and
32% at 6 and 12 months. The results are better than after
standard PTA, with TLR between 39% and 78% after
PTA16,17 and 65% at 6 months after cutting balloon.18
The results after DEB are better or similar to technically
more demanding strategies such as cryoplasty and stent-
ing,19-21 rotational atherectomy, directed atherectomy,
and laser atherectomy, with TLR of 42%,22 31% to
75%,23-27 and 48% to 51%,28,29 respectively. Also the re-
sults of directional atherectomy alone24-27 or combined
with heparin-coated stent grafts30 could not reach better
results at 12 months, with 60% requiring additional PTA.26
The problem of recurrent in-stent RE might not be
solved with stenting, debulking technology, or DEB alone;
therefore, appropriately powered trials are required to eval-
uate the role of different technologies and strategies to
improve the results of treatment of RE in the peripheral
JOURNAL OF VASCULAR SURGERY
398 Herten et al February 2015arteries. Promising results could be reached by standard
PTA combined with brachytherapy31 or drug-eluting
stents (DES),32 but long-term results are still lacking.
The disparate results between DN and RE might be
due to different efﬁcacies of PTX distribution in DN or
RE lesions. Several animal studies demonstrated that PTX
reaches the target, the smooth muscle cell (SMC) layer,
despite intimal plaque in DN stenotic vessels.33,34 In RE le-
sions, a vascular injury is seen after PTA and after stenting
that leaves a stimulus for subsequent repair mechanism.
Stimulation of the mitotic cell cycle is the ﬁnal common
pathway that leads to intimal hyperplasia after vascular
injury. SMCs convert from the contractile phenotype to a
dedifferentiated synthetic phenotype that starts to secrete
extracellular matrix components. RE occurs when this
proinﬂammatory regenerative process is not counterbal-
anced by appropriate stimuli for matrix-degrading enzymes.
The composition of the extracellular matrix components
changes from a provisional ﬁbrin-rich to a permanent ma-
trix. These changes are accompanied by a reduced SMC
density.35 Because the innermost vessel layer forming the
RE consists mainly of noncellular material, the cytotoxic ef-
fect of the PTX may not be able to reach the cellular layer.36
Atherectomy could offer the possibility to remove these in-
ner layers enabling the PTX to reach the target cells.
In the coronary arteries, DEB angioplasty is currently
indicated for in-stent RE.37 Findings from a world-wide
registry of the coronary SeQuent Please DEB (B. Braun
Melsungen AG, Melsungen, Germany) suggested that
PTX-DEB angioplasty is more effective in bare mental
stent RE compared with DES RE, independent of stent
design.38 Recent studies provide robust evidence suggest-
ing that DEBs are as effective as ﬁrst-generation DESs
for patients with RE after implantation of DESs39 and
that the use of a different drug (switch strategy) in patients
with coronary DES in-stent RE has been advocated from
the Restenosis Intra-Stent: Balloon Angioplasty vs Drug-
Eluting Stent (RIBS III) trial by Alfonso et al.40
Even if the outcomes of same therapy concepts can be
different between the coronary and peripheral arteries, the
advantage of DEBs is the combination of effectiveness and
simplicity of use. By removing the need for an additional
stent layer, DEBs might become the treatment of choice
in the future. Results with DEBs are likely to vary according
to the underlying arterial wall composition (ie, neointimal
hyperplasia, neoatherosclerosis). In the future, image-
guided procedures could enable characterization of the
heterogenous tissue causing RE and theoretically drive
the decision on an optimal, tailored treatment to ulti-
mately improve outcomes.41,42
The main limitation of our study is the limited patient
numbers treated with two different DEBs and the lack of
randomization. In addition, the inferior results in the RE
group are driven by the high percentage of patients treated
for in-stent RE. Furthermore, the lower baseline ABIs and
the longer lesions in the RE group imply that those lesions
are at higher risk and that the RE group could be expected
to have lower patency after the DEB angioplasty. However,the results were obtained under real-life conditions in
consecutively treated patients.
The present data mirror a tendency toward a treatment
modiﬁcation regarding DEBs for DN and RE lesions. The
results do not offer evidence but the necessity to investigate
in a future RCT on DEB indication. A proof of concept is
still an issue of debate concerning DN and RE lesions.
CONCLUSIONS
The data suggest that use of DEBs is effective for DN
femoropopliteal lesions. The results of DEBs for RE may
be inferior and possibly comparable with other more tech-
nically demanding strategies. Future evaluation needs to
show whether better results can been obtained in combina-
tion with debulking procedures. Here, the endovascular
approach should ideally combine mechanical and biological
effects without additional metal in the artery.
The advantage of DEB treatment is that nothing is left
behind in contrast to standard of care for long femoropo-
pliteal lesions by stent implantation. Further and secondary
revascularizations can be performed more easily without
preimplanted foreign material.
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